Biotech, Diagnostics, Financing

Exact Sciences raises $137.7 million in public offering financing

Posted on 15 April 2014

Tags: ,

Exact Sciences has completed a secondary stock offering, selling 11.5 million shares of common stock.

The transaction, which includes an extra 1.5 million shares sold through the underwriters' option to buy additional stock, will give the Madison company $137.7 million in net proceeds.

The money is expected to be used to work toward Food & Drug Administration approval of Cologuard, Exact Sciences' non-invasive, stool-based, DNA test for colorectal cancer, currently under FDA review.

It will also go for commercializing Cologuard, if approved, and developing additional products.

For further financing deal information visit Current Agreements (subscription required)

 

Related

Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary

View: Current Partnering’s Financing Scorecard – view top life science financing deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply